Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Vir Biotechnology (NASDAQ:VIR) announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart and elebsiran combination for chronic hepatitis delta (CHD). The treatment achieved 100% virologic response with HDV RNA suppression, showing undetectable virus levels in 41% of participants at Week 24, increasing to 64% by Week 36, and reaching 80% by Week 60. The combination therapy demonstrated a strong safety profile with no severe treatment-related adverse events. Based on these results, Vir plans to initiate the Phase 3 ECLIPSE registrational program in early 2025, comprising three clinical trials to evaluate the combination therapy against existing treatments.
Vir Biotechnology (NASDAQ:VIR) ha annunciato risultati positivi dal trial clinico di fase 2 SOLSTICE che valuta la combinazione di tobevibart ed elebsiran per l’epatite delta cronica (CHD). Il trattamento ha raggiunto una risposta virologica del 100% con soppressione dell’RNA dell’HDV, mostrando livelli di virus non rilevabili nel 41% dei partecipanti alla Settimana 24, aumentando al 64% alla Settimana 36, e raggiungendo l’80% alla Settimana 60. La terapia combinata ha dimostrato un profilo di sicurezza solido senza eventi avversi gravi correlati al trattamento. Sulla base di questi risultati, Vir prevede di avviare il programma registrativo di fase 3 ECLIPSE all’inizio del 2025, comprendente tre trial clinici per valutare la terapia combinata rispetto ai trattamenti esistenti.
Vir Biotechnology (NASDAQ:VIR) anunció resultados positivos del ensayo clínico de fase 2 SOLSTICE que evalúa la combinación de tobevibart y elebsiran para la hepatitis delta crónica (CHD). El tratamiento logró una respuesta virológica del 100% con supresión de ARN del HDV, mostrando niveles virales indetectables en el 41% de los participantes en la Semana 24, aumentando al 64% en la Semana 36, y alcanzando el 80% en la Semana 60. La terapia combinada demostró un perfil de seguridad sólido sin eventos adversos graves relacionados con el tratamiento. Basado en estos resultados, Vir planea iniciar el programa registral de fase 3 ECLIPSE a principios de 2025, que comprende tres ensayos clínicos para evaluar la terapia combinada en comparación con tratamientos existentes.
Vir Biotechnology (NASDAQ:VIR)는 만성 델타 간염(CHD)을 위한 tobevibart와 elebsiran의 조합을 평가한 SOLSTICE 2상 임상 시험에서 긍정적인 결과를 발표했습니다. 치료는 100%의 바이러스학적 반응을 달성하며 HDV RNA 억제를 나타냈고, 24주째 참가자 중 41%에서 바이러스 수치가 검출되지 않았으며, 36주째에 64%, 60주째에는 80%에 도달했습니다. 이 조합 요법은 심각한 치료 관련 부작용 없이 강력한 안전성을 보여주었습니다. 이러한 결과를 바탕으로 Vir는 2025년 초에 기존 치료법과 조합 요법을 평가하기 위해 세 개의 임상 시험을 포함하는 ECLIPSE 3상 등록 프로그램을 시작할 계획입니다.
Vir Biotechnology (NASDAQ:VIR) a annoncé des résultats positifs de l’essai clinique de phase 2 SOLSTICE évaluant la combinaison de tobevibart et d’elebsiran pour l’hépatite delta chronique (CHD). Le traitement a obtenu une réponse virologique de 100% avec suppression de l’ARN du VHD, montrant des niveaux viraux indétectables chez 41 % des participants à la Semaine 24, passant à 64 % à la Semaine 36, et atteignant 80 % à la Semaine 60. La thérapie combinée a démontré un bon profil de sécurité sans événements indésirables graves liés au traitement. Sur la base de ces résultats, Vir prévoit de lancer le programme d’enregistrement de phase 3 ECLIPSE début 2025, comprenant trois essais cliniques pour évaluer la thérapie combinée par rapport aux traitements existants.
Vir Biotechnology (NASDAQ:VIR) hat positive Ergebnisse aus der SOLSTICE-Phase-2-Studie bekannt gegeben, die die Kombination von tobevibart und elebsiran bei chronischer Deltahepatitis (CHD) bewertet. Die Behandlung erreichte eine virologische Antwort von 100% mit einer Unterdrückung der HDV-RNA, wobei bei 41 % der Teilnehmer in Woche 24 keine nachweisbaren Viruswerte vorlagen. Dies stieg in Woche 36 auf 64 % und erreichte in Woche 60 80 %. Die Kombinationstherapie zeigte ein starkes Sicherheitsprofil ohne schwere behandlungsbedingte unerwünschte Ereignisse. Basierend auf diesen Ergebnissen plant Vir, Anfang 2025 das registrierungsrelevante Phase-3-ECLIPSE-Programm zu starten, das drei klinische Studien zur Bewertung der Kombinationstherapie im Vergleich zu bestehenden Behandlungen umfasst.
Positive
- 100% virologic response achieved in combination therapy
- Undetectable virus levels increased from 41% (Week 24) to 80% (Week 60)
- 47% ALT normalization in combination de novo cohort by Week 24
- FDA granted fast track designation
- EMA issued positive opinion for orphan drug designation
- No treatment-related severe adverse events reported
Negative
- Phase 3 trials won’t begin until first half of 2025
- Currently no approved treatment in the United States
Insights
The Phase 2 SOLSTICE trial results represent a significant breakthrough in CHD treatment. The combination of tobevibart and elebsiran achieved 100% virologic response with impressive viral clearance rates increasing from 41% at Week 24 to 80% by Week 60. The safety profile is particularly noteworthy, with no severe treatment-related adverse events or discontinuations.
The planned Phase 3 ECLIPSE program, structured as three distinct trials, demonstrates a comprehensive approach to market entry. The Fast Track designation from FDA and potential EMA orphan drug status could accelerate approval timelines. With no currently approved treatments in the US for CHD, which typically progresses to cirrhosis within 5 years, this therapy could capture significant market share.
This development represents a major market opportunity in the untapped CHD treatment space. The monthly dosing schedule and strong efficacy data position this combination therapy favorably against potential competitors. The three-pronged Phase 3 program is strategically designed to support both US approval and European market access, with ECLIPSE 3 specifically addressing pricing considerations.
The fast track designation and potential orphan drug status could provide market exclusivity and premium pricing potential. Given the severe nature of CHD and lack of approved treatments in the US, successful commercialization could generate substantial revenue for Vir Biotechnology.
– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –
– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –
– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –
– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –
– New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET –
SAN FRANCISCO–(BUSINESS WIRE)– Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly achieved 100% virologic response and rapid hepatitis delta virus (HDV) RNA suppression. HDV RNA below the lower limit of quantification (< LLOQ), target not detected (TND), the best measure that the virus is cleared from the body, was achieved in 41% (13/32) of participants at Week 24 rising to 64% (14/22) of participants by Week 36. In a cohort that reached Week 60, 80% (4/5) achieved HDV RNA TND.
These data were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.
CHD is a chronic inflammatory liver disease caused by HDV1. It is the most severe form of chronic viral hepatitis2 and on average, people living with CHD will progress to cirrhosis and liver failure within 5 years3. There is no approved treatment in the United States. The objective of therapy is to clear the virus, and combination therapy offers the potential to do so by tackling the viral lifecycle through multiple mechanisms.
“Achieving HDV RNA suppression with a safe, well-tolerated, and conveniently dosed treatment could be transformative for people living with hepatitis delta. The impressive rates of virologic suppression seen in the SOLSTICE Phase 2 data suggest that tobevibart and elebsiran have the potential to significantly improve patient outcomes,” said Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris-Cité, and Head of the unit Viral Hepatitis UMR1149 at INSERM, France. “New, effective therapeutic options are urgently needed, and I am excited to see this combination advance into a registrational Phase 3 program.”
Primary Endpoint Analysis from the Phase 2 SOLSTICE Trial
Clinical trial participants were randomized to receive tobevibart 300 mg monotherapy every two weeks (n=33) or a combination of tobevibart 300 mg and elebsiran 200 mg every four weeks (combination de novo arm, n=32). In addition, the participants from previous tobevibart or elebsiran monotherapy cohorts could rollover to receive the combination of tobevibart 300 mg and elebsiran 200 mg every four weeks (combination rollover, n=13). Rates of virologic suppression were evaluated at Week 24, and further assessed at Weeks 36, 48 and 60 in those participants that had reached each timepoint. Further monitoring will continue up to 192 weeks.
Rapid and Sustained Virologic Suppression – 100% of participants across combination arms achieved an HDV RNA ≥2 log10 decrease or below limit of detection (LOD) at Week 24, and this rate was sustained over time in all participants at Weeks 36 (22/22) and those in the rollover cohort that reached Week 60 (5/5).
HDV RNA TND was achieved in 41% (13/32) of participants across combination arms at Week 24 and this rose to 64% (14/22) at Week 36. By week 60, this had risen further with 80% (4/5) of participants in the rollover cohort having achieved no detectable viral RNA.
Approximately 90% of participants receiving the combination achieved reductions in hepatitis B surface antigen (HBsAg) values below <10 IU/mL at Week 24, with sustained responses at later time points. This indicates suppression of the key biologic mechanisms that HDV requires for viral replication.
ALT Normalization – Alanine aminotransferase (ALT) decreased in most participants between Day 1 and Week 24 and normalized in 47% (15/32) of participants in the combination de novo cohort and 56% (5/9) in the rollover cohort by Week 24. These rates were sustained at Week 36.
Combined Endpoints – The protocol defined combined endpoint of HDV RNA decrease ≥ 2 log10 compared to baseline or HDV RNA below LOD and ALT normalization at Week 24 was observed in 47% (15/32) of participants in the combination de novo arm.
The more stringent composite endpoint of HDV RNA TND and ALT normalization was achieved in 19% (6/32) of participants in the combination de novo arm at Week 24, which increased to 27% (6/22) by Week 36. This trend was reflected in the combination rollover cohort in which 33% (3/9) of participants achieved this endpoint at Week 24 and 40% (2/5) at Week 60. Rates of HDV RNA suppression and ALT normalization were similar between non-cirrhotic and cirrhotic participants across combination arms.
Safety Profile – The safety profile of tobevibart and elebsiran is consistent with previous studies. Treatment-emergent adverse events (TEAEs) were generally mild or moderate and transient across all treatment groups, with influenza-like illness being the most common event. No ALT flares were observed. There were no study-related discontinuations in the combination arms, and no treatment-related severe adverse events (SAEs) were reported.
“People living with hepatitis delta in the US have no approved treatment options, and therapies are limited globally. At Vir Biotechnology we are committed to changing that,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “We are confident that our regimen has the potential to deliver transformative benefits for patients, and we will build on our strong SOLSTICE data to start our Phase 3 registrational ECLIPSE program as soon as possible in 2025.”
Phase 3 Registrational ECLIPSE Program
Following a meeting with the FDA, Vir Biotechnology finalized the design of the Phase 3 registrational clinical program, ECLIPSE, which evaluates the tobevibart and elebsiran combination in people living with CHD. This program, which will commence in the first half of 2025, will include three randomized, controlled trials designed to evaluate the combination therapy in comparison to deferred treatment or bulevirtide. All studies will enroll both cirrhotic and non-cirrhotic participants. ECLIPSE 1 and 2 are Phase 3 trials designed to provide the registrational efficacy and safety data needed for submission to global regulatory agencies. ECLIPSE 3 is a Phase 2b trial designed to provide important supportive data, particularly in Europe, to help establish appropriate pricing and reimbursement in key markets.
- ECLIPSE 1 will assess the efficacy and safety of tobevibart and elebsiran compared to deferred treatment in regions such as the U.S. where bulevirtide is not available or its use is limited.
- ECLIPSE 2 will evaluate the efficacy and safety of switching to tobevibart and elebsiran in people with CHD who have not achieved viral suppression with bulevirtide therapy.
- ECLIPSE 3 is a Phase 2b head-to-head trial to evaluate tobevibart and elebsiran compared with bulevirtide in bulevirtide-naïve patients.
In June 2024, the U.S. Food and Drug Administration (FDA) granted fast track designation for the combination of tobevibart and elebsiran for the treatment of CHD. This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Vir Biotechnology announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of CHD. This designation supports the development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need.
Investor Conference Call
Vir Biotechnology will host an investor conference call on November 19, 2024 at 5.15 a.m. PT / 8.15 a.m. ET. A live webcast will be available on https://investors.vir.bio/ and will be archived on www.vir.bio for 30 days.
About the Phase 2 SOLSTICE Trial
SOLSTICE is a Phase 2 study to evaluate the safety, tolerability, and efficacy of tobevibart, alone or in combination with elebsiran, in people with chronic hepatitis delta. This Phase 2 study is a multi-center, open-label, randomized study. Primary endpoints include proportion of participants with undetectable hepatitis delta virus (HDV) RNA (defined as HDV RNA equal or greater than 2 log10 decrease from baseline or below limit of detection) up to week 24, alanine aminotransferase (ALT) normalization (defined as ALT below upper limit of normal) up to week 24, and treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) up to 118 weeks. Secondary endpoints include proportion of participants with undetectable HDV RNA and different timepoints and up to 192 weeks. More information about this trial can be found at clinicaltrials.gov (NCT05461170).
About Tobevibart and Elebsiran
Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis B and patients with chronic hepatitis delta.
Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis B and patients with chronic hepatitis delta. It is the first asset in Vir Biotechnology’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies.
Tobevibart and elebsiran are also being evaluated as a potential functional cure for chronic hepatitis B. Vir Biotechnology recently presented positive safety and efficacy end-of-treatment results from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, alone or in combination with pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B in a late-breaker oral presentation at AASLD The Liver Meeting®.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. It’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
References:
1 NIH National Institute of Diabetes and Digestive and Kidney Diseases Hepatitis D – NIDDK (nih.gov), accessed September 2024
2 WHO Hepatitis Delta Factsheet – Hepatitis D (who.int), accessed September 2024
3 CDC What is Hepatitis D – FAQ | CDC
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir Biotechnology’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir Biotechnology’s strategy and plans, the potential clinical effects of tobevibart and elebsiran, the potential benefits, safety and efficacy of tobevibart and elebsiran, the timing, nature and significance of data from Vir Biotechnology’s multiple ongoing trials evaluating tobevibart and elebsiran, Vir Biotechnology’s plans and expectations for its CHD and CHB programs, and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by Vir Biotechnology’s competitors; changes in expected or existing competition; delays in or disruptions to Vir Biotechnology’s business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118939659/en/
Media
Arran Attridge
Senior Vice President, Corporate Communications
Investors
Richard Lepke
Senior Director, Investor Relations
Source: Vir Biotechnology, Inc.
FAQ
What were the key results of VIR’s SOLSTICE Phase 2 trial for hepatitis delta?
The trial showed 100% virologic response with HDV RNA suppression, achieving undetectable virus levels in 41% of participants at Week 24, rising to 64% by Week 36, and 80% by Week 60.
When will VIR begin its Phase 3 ECLIPSE program for hepatitis delta treatment?
Vir Biotechnology plans to initiate the Phase 3 ECLIPSE registrational program in the first half of 2025.
What regulatory designations has VIR received for its hepatitis delta treatment?
The FDA granted fast track designation in June 2024, and the EMA Committee for Orphan Medicinal Products issued a positive opinion for orphan drug designation.
